Results 141 to 150 of about 26,051 (185)

Temporal shifts in diagnostic testing for cardiac amyloidosis across U.S. health systems. [PDF]

EJNMMI Rep
Motairek I, Abadie B, Higgins A, Jawad ZN, Bhat P, Rubio AC, Hanna M, Jaber WA.   +7 more
europepmc   +1 more source

Apolipoprotein A-IV Cardiac Amyloidosis as a Diagnostic Pitfall: Beyond the Noninvasive Algorithm. [PDF]

JACC Case Rep
Koppelaar AJ, Zwetsloot PP, von der Thüsen JH, Lam KH, Gilbertson JA, Gillmore JD, Michels M, Hirsch A.   +7 more
europepmc   +1 more source

Imaging Cardiac Amyloidosis: From Early Diagnosis to Risk Stratification and Evaluation of Treatment Efficacy. [PDF]

J Cardiovasc Dev Dis
Sclafani M, Russo D, Oikonomou G, Camastra G, Belmonte E, Tini G, Rotunno R, Chimenti C, Lanzillo C, Musumeci B, Castiello T, Regondi S, Ricci R, Cacciotti L, Arcari L.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac Amyloidosis

Critical Care Nurse, 2010
Amyloidosis is a clinical disorder caused by the extracellular deposition of misfolded, insoluble aggregated protein with a characteristic ss pleated sheet configuration that produces apple-green birefringence under polarized light when stained with Congo red dye.
Harit V, Desai, Wilbert S, Aronow, Stephen J, Peterson, William H, Frishman   +3 more
openaire   +4 more sources

Cardiac amyloidosis

Current Treatment Options in Cardiovascular Medicine, 1999
No definitive therapy is available for cardiac amyloidosis. Treatment with alkylating agents such as melphalan has improved survival. Patients who do not respond to melphalan have benefited from high-dose chemotherapy with cyclophosphamide followed by peripheral stem cell transplantation.
, Kashyap, , Hosenpud
openaire   +4 more sources

Cardiac amyloidosis

Expert Review of Cardiovascular Therapy, 2014
Amyloidosis is a condition characterized by the extracellular deposition of insoluble fibrillar protein in tissues and various organs including the heart. This review summarizes the clinical manifestations and diagnostic treatment approaches for cardiac amyloidosis.
Syed Wamique, Yusuf, Amirreza, Solhpour, Jose, Banchs, Juan C, Lopez-Mattei, Jean-Bernard, Durand, Cezar, Iliescu, Saamir A, Hassan, Muzaffar H, Qazilbash   +7 more
openaire   +2 more sources

The genetics of cardiac amyloidosis

Heart Failure Reviews, 2021
Heritable cardiac amyloidosis (CA) is an underrecognized cause of morbidity and mortality in the USA. It results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM). Over 150 different pathologic point mutations within the transthyretin gene have been
Scott Arno, Jennifer Cowger
openaire   +2 more sources